questionText: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that access to CAR-T therapies for mantle cell lymphoma is consistent across the UK, in the context of its continued availability in Scotland.
answerText: The National Institute for Health and Care Excellence (NICE) is re-evaluating brexucabtagene autoleucel following managed access through the Cancer Drugs Fund to determine whether it should be recommended for routine National Health Service funding. NICE’...
heading: Blood Cancer: Immunotherapy